ARTICLE | Clinical News
Subcutaneous MOR103: Phase I data
December 3, 2012 8:00 AM UTC
A Phase I trial in 32 healthy volunteers showed that single doses of 0.5, 1 and 2 mg/kg subcutaneous MOR103 were well tolerated and had "high neutralizing potency" comparable to a single 2 mg/kg dose ...